Age at menopause and hormone replacement therapy as risk factors for head and neck and oesophageal cancer (Review).
Age at menopause and hormone replacement therapy as risk factors for head and neck and oesophageal cancer (Review). Oncol Rep. 2017 Aug 01;: Authors: McCarthy CE, Field JK, Marcus MW Abstract There were ~986,000 cases of head and neck cancer (HNC) and oesophageal cancer diagnosed worldwide in 2012. The incidence of these types of cancer is much higher in males than females, although this disparity decreases in the elderly population, suggesting a role for hormones as a risk factor. This systematic review investigates the potential role of female hormones [age at menopause and use of hormone replacement therapy (HRT)] as risk factors for HNC/oesophageal squamous cell carcinoma (SCC). The electronic databases MEDLINE, Web of Science, EMBASE and Cochrane were searched. Only studies with at least 50 cases of HNC/oesophageal SCC, with data on age at menopause, smoking, alcohol, age and socioeconomic status or educational attainment, were included. The Newcastle Ottawa Scale was used for assessing risk of bias. Eight studies met the inclusion criteria (5 oesophageal SCC, 2 HNC and 1 combined oesophageal SCC and HNC). HRT was shown to reduce the risk of HNC (HR, 0.78; 95% CI, 0.61-0.99) in one study. Our results showed that earlier age at menopause is a risk factor for oesophageal SCC, with women entering menopause at 50 years. Similar, but less striking, results were observed for HNC. HRT was found to reduce the...
In this issue of the International Journal of Radiation Oncology • Biology • Physics, Escande et al (1) report a phenomenal single-institution experience with interstitial 192Ir low-dose-rate or pulsed-dose-rate brachytherapy for squamous cell carcinoma of the glans penis. Their experience, which spans 45 years and involves more than 200 patients with a med ian follow-up of more than 10 years, indisputably establishes interstitial brachytherapy as an effective penile-sparing modality for squamous cell carcinoma of the glans.
The breadth of a health insurance plan's network typically dictates the level of access that a consumer will have to primary care physicians, specialists, and other types of health care providers. Thus, the comprehensiveness of plan networks —including whether consumers have access to in-network cancer centers—is a critical component of quality health insurance. In response to increased health care costs and pressure to keep premiums down, health plans have begun to adopt “narrow network” plans. A narrow network plan has been ty pically defined as a plan with a more limited number of providers as co...
Postmastectomy radiation therapy (PMRT) generally improves locoregional control and overall survival in patients with pathologic lymph node-positive breast cancer, as evidenced by meta-analyses of randomized trials (1). Nevertheless, controversy persists regarding whether PMRT is indicated for all such patients, especially those with clinical T1-T3N1 who receive neoadjuvant chemotherapy (NAC) with a complete pathologic response in the involved axillary lymph nodes (ypN0). For such patients, the current standard recommendation is to offer entry into clinical trials comparing regional nodal irradiation (RNI) versus no RNI (2...
To the Editor: We read with interest the recently published report by Vashistha et al, “Radical cystectomy compared to combined modality treatment for muscle-invasive bladder cancer: A systemic review and meta-analysis” (1). The authors searched 7 databases, found 19 studies evaluating 12,380 subjects, and finally selected 8 studies encompassing 9554 subjects eligible for m eta-analysis. They reported no difference in overall survival at 5 years or progression-free survival at 10 years within this cohort of 9554 patients.
In this issue of Oncology Scan, the Gynecologic Cancer editors discuss publications of molecular analysis of primary cervical cancer as part of the Cancer Genome Atlas project and advancements in 3-dimensional (3D) brachytherapy (BT) for cervical cancer. The genomic study highlights a specific type of cervical cancer classified as keratin-low, which has lower survival with surgery, and further work needs to be done to determine whether this difference in outcome holds true for patients treated with definitive chemoradiation therapy.
We read with interest the recent Red Journal article “Radical Prostatectomy Versus Radiation and Androgen Deprivation Therapy for Clinically Localized Prostate Cancer: How Good Is the Evidence?” by Roach et al (1). This was a thoughtful and critical analysis of the complex literature relating to irradiation versus prostatectomy in men with locali zed prostate cancer. Overall, the authors assigned low reliability scores to many of the studies evaluated, citing an inadequate (or unreported) duration of androgen deprivation therapy (ADT) with radiation therapy for intermediate- or high-risk disease, unadjuste...
The landmark Prostate Testing for Cancer and Treatment (ProtecT) study was published in September 2016 (1). This is the first randomized trial to answer the question of which treatment among surgery, radiation therapy, and active surveillance is best for low-risk prostate cancer. The fact that the authors were able to perform and complete this study deserves immense credit.
This report presents a randomised controlled trial of a mindfulness-based intervention during chemotherapy and suggests that care is needed in employing mindfulness-based interventions in acute health treatment contexts.
CONCLUSION: Indication, procedure and follow-up of ablative therapies in prostate cancer require specific modalities. They must be respected in order to optimize the results and to obtain a precise and objective evaluation for defining future indications. PMID: 28918872 [PubMed - as supplied by publisher]
CONCLUSION: Based on new imaging and biopsy, ablative therapies will probably increased its role in the future in management of localize prostate cancer. The multiple ongoing trials will certainly be helpful to better define their indications and limits. PMID: 28918871 [PubMed - as supplied by publisher]
More News: Alcoholism | Cancer | Cancer & Oncology | Carcinoma | Databases & Libraries | Education | Epidemiology | Esophagus Cancer | Head and Neck Cancer | Hormone Replacement Therapy | Hormones | Laboratory Medicine | Men | Menopause | Science | Skin Cancer | Smokers | Squamous Cell Carcinoma | Study | Women